Letter by Koh Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Vallejo-Vaz et al1 reported robust novel evidence for the short- and long-term benefits of lowering low-density lipoprotein cholesterol (LDL-C) for the primary prevention of cardiovascular disease among individuals with primary elevations of LDL-C ≥190 mg/dL by performing post hoc analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) randomized, placebo-controlled trial, and observational posttrial long-term follow-up, after excluding individuals with evidence of vascular disease at baseline. Long-term effectiveness and the safety of pravastatin in patients with …